Mesenchymal Stem Cell Secretome In Severe Cases of COVID-19

Summary

This study is a multi-centre randomized controlled trial involving severe covid-19 patients. The intervention group will receive mesenchymal stem cell secretomes and standard covid-19 therapy, while the control group receive placebo and standard covid-19 therapy. Clinical presentation, inflamatory marker, laboratory and radiological parameters, RT-PCR conversion, safety profile, and mortality rate will be monitored for a maximum of 14 days after intervention.

Timeline

Start

2020-08-10

Primary completion

2021-07-30

Completion

2021-11-14

Drugs

Indications